A young jumper prospect comes in for a pre-purchase exam sound, clean on flexions, and quiet under saddle. The radiographs look unremarkable. Six months later, in full work with a new owner, the horse comes up lame behind a fetlock that a scan now shows has been quietly failing for some time. Nothing on the sale-day paperwork explains the gap between the two. Increasingly, veterinarians researching bone drugs in young performance horses say the explanation may not be a missed diagnosis at all. It may be a drug that was never disclosed.
The drugs are bisphosphonates, sold under the brand names Tildren (tiludronate disodium) and Osphos (clodronate disodium), and the U.S. Food and Drug Administration approved both in 2014 for a single, narrow purpose: controlling the clinical signs of navicular syndrome in horses four years of age or older. That label is specific for a reason. The FDA has never evaluated the drugs' safety in horses younger than four, and the mechanism behind them — slowing the activity of osteoclasts, the cells that break down old bone so new bone can replace it — is exactly the process a growing skeleton depends on to get stronger.
What the Drug Actually Does
Bisphosphonates do not build bone. They slow its turnover. In a mature horse with a chronic, localized problem like navicular syndrome, that trade-off can relieve pain without much downside, because the skeleton has already finished the work of remodeling itself into an adult's. In a two- or three-year-old sport-horse prospect whose cannon bones, sesamoids, and joint surfaces are still actively reshaping themselves under the stress of early training, the same mechanism raises a different question: what happens when the signal that would normally tell a rider or a veterinarian that a young horse is overloaded gets muted along with the pain.
A 2022 review in the journal Animals, by researchers Fabio Vergara-Hernandez, Brian D. Nielsen, and Aimee Colbath, laid out the concern in mechanistic terms: impairing osteoclast function could allow skeletal microdamage to accumulate, and impair the bone's ability to heal it, without producing the pain that would normally prompt rest or veterinary attention. The worry is not simply that the drug masks existing lameness. It is that it may remove the early-warning system a young, actively remodeling skeleton relies on.
The clinical evidence on actual harm remains thinner than the theoretical concern. A small pilot study published in BMC Veterinary Research in 2018 by Heather Richbourg, Colin Mitchell, Ashley Gillett, and Margaret McNulty found no measurable effect on bone structure or remodeling kinetics in young horses given tiludronate or clodronate over 60 days — a reassuring result, though the trial was small and short relative to a horse's growth window. More recently, a 2025 study in the Equine Veterinary Journal by Tippen and colleagues found that clinically relevant doses of tiludronate did not affect bone remodeling in pasture-exercised horses, the most direct evidence yet that correctly dosed, on-label use is not the hazard critics once feared. What none of that research addresses is the population veterinarians say is actually at risk: horses under four, dosed off-label, often more than once, to get a young prospect through a radiograph rather than through a diagnosis.
Where the Off-Label Use Begins
That off-label pattern is best documented on the Thoroughbred side of the industry, where bisphosphonates have been used on weanlings and yearlings specifically to obscure radiographic evidence of sesamoiditis, an inflammatory change in the sesamoid bones and their supporting ligaments behind the fetlock, ahead of public auction. Auburn University equine surgeon Dr. Lindsey Boone, an associate professor of equine surgery and sports medicine, has cautioned that appropriate use depends on matching the drug to the horse's age and the actual reason for treatment, avoiding concurrent NSAIDs, monitoring kidney function, and keeping the drug well clear of any recognized competition — guidance built for a mature horse with a defined orthopedic diagnosis, not a young horse being prepared for a sale.
US Equestrian's own rulebook already reflects the FDA's line: under the federation's drugs and medications rule, administering a bisphosphonate is a prohibited practice unless the horse is four years of age or older and the drug used is one of the two FDA-approved bisphosphonates. That rule protects the horse once it enters a USEF-recognized competition. It does nothing for the horse before that point — during the private treaty sale, the futurity prep, or the auction ring, where no steward is drawing blood and no post-class testing applies.
What a buyer can actually do:
Ask directly whether a young prospect has received any bisphosphonate, and when.
Request a blood or urine test for bisphosphonates as part of the pre-purchase exam — the same right Thoroughbred buyers now have in writing.
Treat a clean, quiet vetting on a horse under five with the same scrutiny as a clean vetting on a horse with a known joint history.
Remember that tiludronate carries an FEI detection time of 28 days, while other bisphosphonates are banned outright with zero tolerance — a positive test has consequences that outlast the sale.
Racing Rewrote the Contract. The Sport Horse World Has Not
The Thoroughbred sales industry did not solve this problem quietly. After veterinarians and buyers raised alarms, Keeneland, Fasig-Tipton, and Ocala Breeders' Sales rewrote their conditions of sale, effective July 2019, to explicitly ban off-label bisphosphonate use in horses under four and to give buyers a contractual right to test a purchased horse's blood for the drug, with the right to rescind the sale within twenty-four hours of a positive result. The American Association of Equine Practitioners went further still, stating plainly that bisphosphonates are inappropriate for any horse, regardless of age, offered for sale at public auction as an athlete, given how little is still known about how long the drugs persist or what they do over time.
No comparable clause turned up in the publicly posted terms of the Canadian Warmblood Auction, and none appears in the materials published around USHJA's Young Jumper Championships, which showcase four- through eight-year-old prospects at exactly the age where this question matters most. That is not proof no sport-horse sale anywhere addresses it. It is proof that the industry has not made the same public commitment racing did, at a moment when a young jumper or hunter prospect can change hands for as much as a well-bred yearling.
The research so far is genuinely more reassuring than alarming when the drug is used as labeled, in a mature horse, for the condition it was approved to treat. The problem was never really the drug. It is that the sport-horse market has never had to answer, in writing, the question the racing industry finally forced itself to answer six years ago: prove the vetting is real, or let the buyer check for herself.
0 comments